Vitura Health
Vitura Health is set to join the S&P/ASX All Ordinaries index from March 20, a development chief executive Rodney Cocks described as a reflection of the company's rapid expansion.
The index tracks the 500 largest companies listed on the ASX and is widely regarded as a broad measure of the Australian stock market, covering 89% of the country's total equity market.
"We are thrilled that Vitura Health will soon be included in the S&P/ASX All Ordinaries Index," Cocks said. "This elevation is not only tangible evidence of the significant progress the company has made since listing on the ASX but, importantly, it should also enhance our visibility with the investment community and improve the liquidity of the company's shares."
Vitura shares were trading at A$0.50c, a gain of 5.6% on Friday's closing price.
Puro
New Zealand cannabis cultivator Puro has selected Elevated Signals as its manufacturing execution system (MES) after a "rigorous procurement process" that evaluated numerous seed-to-sale and track-and-trace platforms from around the world.
According to Puro, the Canada-based company Elevated Signals is well positioned to improve operational efficiency, oversee data collection, and maintain compliance with pharmaceutical standards.
Puro co-founder and cultivation director Tom Forrest said: "Collecting data is crucial not only to achieve the best outcomes in cultivation, but also to guide our decision making and improve the productivity of our team.
"Elevated Signals will enable us to digitally track the entire life cycle of our crops, ensuring compliance at every stage."
Elevated Signals co-founder and chief executive Amar Singh said its platform has been "battle tested" in Canada.
"We're dedicated to bringing best practices in operational excellence to cannabis businesses across the globe," he said. "We're thrilled to be expanding into the emerging market of New Zealand through our partnership with Puro and its talented team."
The Elevated Signals platform replaces paper records, spreadsheets, and outdated software with a digital system that handles inventory, quality recordkeeping, regulatory compliance, and environmental data.
MGC Pharmaceuticals
MGC Pharmaceuticals has secured an additional A$734,000 through a convertible securities funding arrangement with Mercer Street Global Opportunity, a fund overseen by US-based institutional manager Mercer Street Capital Partners.
The ASX-listed company will issue 550,000 convertible notes to Mercer, each carrying a face value of US$1.
The proceeds will go toward working capital.
MGC shares jumped 12.5% during Wednesday's session, reaching $0.009c per share and giving the company a market capitalisation of $22.93m.
Incannex Healthcare
Incannex Healthcare has announced its intention to develop and manufacture GMP-grade psilocybin for use in clinical trials and potential broader commercial applications.
The ASX-listed company has engaged drug manufacturer Catalent to produce the compound, following a review of data from the phase II PsiGAD trial, which investigated psilocybin's effects on generalised anxiety disorder.
Incannex said interim findings from the trial provided it with the "confidence to proceed with formulation development and cGMP manufacture of its own psilocybin".
Chief scientific officer Dr Mark Bleackley said: "This therapy has the potential to help millions of people whose lives are seriously impacted by severe anxiety and for whom current treatment options have not been effective.
"We look forward to working with Catalent on the continued development of this exciting drug product."
Cann Global
Cann Global has indicated that "intended acquisitions" — first announced nearly six months ago — will allow the company to improve operational efficiency, build capital reserves, and generate long-term value for shareholders.
In a statement to the ASX, Cann Global acknowledged it "understood the inconvenience" of such a drawn-out process, but said it was essential to carry out "complete and thorough due diligence with each acquisition proposal".
Cann Global first entered a trading halt in September and has sought several extensions since.
The company is now expected to make a formal announcement on March 24.
Separately, chief operating officer Marion Lesaffre has departed after three years in the role, having previously spent a decade at Cann Global's predecessor entity, Queensland Bauxite.
Managing director Sholom Feldman said Lesaffre had made a "significant contribution to the group" having been instrumental in the "transition and restructuring of the business and success in streamlining operations to reduce costs".
